AlphaGrep UK’s Atrium Therapeutics RNA Stock Holding History

AlphaGrep UK’s Portfolio RNA Stock Details RNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-11,870	Closed	-$159K	–	997
2026 Q1	$159K	Buy	+11,870	New	+$167K	0.05%	738

Other funds holding RNA

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

CRCM LP San Francisco, California $144M AUM 26.42% 1-Year Est. Return

TAL

TIG Advisors LLC New York $2.26B AUM 81.38% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

APCM

Arbiter Partners Capital Management New York $190M AUM 51.6% 1-Year Est. Return

AlphaGrep UK's RNA Position: Q2 2026 in Review

AlphaGrep UK sold out of Atrium Therapeutics (RNA) in Q2 2026, closing a stake of 11,870 shares — an estimated $159K sold.

AlphaGrep UK first reported a position in RNA in Q1 2026 and held it in 1 quarter. The position peaked at $159K in Q1 2026. 139 funds tracked by Wall St. Rank hold RNA as of Q2 2026.

AlphaGrep UK reported no remaining Atrium Therapeutics position as of Q2 2026 after selling out during the quarter.
AlphaGrep UK sold 11,870 Atrium Therapeutics shares in Q2 2026, an estimated $159K.
AlphaGrep UK first reported a position in Atrium Therapeutics in Q1 2026 and held it in 1 quarter.
AlphaGrep UK's Atrium Therapeutics position peaked at $159K in Q1 2026.
139 funds tracked by Wall St. Rank held Atrium Therapeutics as of Q2 2026.

Based on AlphaGrep UK's 13F filing for Q2 2026, filed 14 Aug 2026.